A 36-week, single-arm, open-label study to evaluate the safety and tolerability of ferric citrate in children with hyperphosphatemia related to chronic kidney disease.
To assess the safety and tolerability of ferric citrate in pediatric subjects with hyperphosphatemia related to chronic kidney disease (CKD).
Why this Research Matters
A single arm trial evaluating efficacy of ferric citrate over 36 weeks in pediatric patients with hyperphosphatemia related to CKD.
Who can Participate
12-17 years old, diagnosis of CKD
Study ID
Protocol Number: 23-0073
Meet the Team
Principal Investigator